概括
一名患有霍奇金氏病的患者因胰岛素受体抗体而出现严重的低血糖症. 这种自身抗体模仿了胰岛素的作用,导致血糖危险下降.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤免疫学上.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 霍奇金病的化疗可能会产生复杂的代谢副作用.
- 禁食低血糖是一种罕见但严重的并发症,需要进行调查.
研究的目的:
- 为了调查患有霍奇金病的患者严重禁食低血糖的原因.
- 为了确定患者血清中导致低血糖的因子的性质.
- 探索这种因素对葡萄糖代谢的作用机制.
主要方法:
- 在老鼠脂肪细胞中检测葡萄糖的摄取量.
- 血清免疫球蛋白分量的分离.
- 对胰岛素与人体红细胞结合的研究.
- 使用人类胎盘提取物分析胰岛素受体沉和酸化.
主要成果:
- 患者的血清中含有刺激脂肪细胞吸收葡萄糖的因素.
- 这一因素局限于免疫球蛋白分数.
- 血清因子取代了结合的胰岛素,并与胰岛素受体相互作用.
- 有证据表明,该因素是针对胰岛素受体的自身抗体.
结论:
- 患者的低血糖症是由针对胰岛素受体的自身抗体引起的.
- 这种自身抗体表现出类似胰岛素的活性.
- 这一案例突出了霍奇金病中罕见的副瘤或与治疗相关的自身免疫并发症.
相关概念视频
Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...


